Plectin-1 is a biomarker of malignant pancreatic intraductal papillary mucinous neoplasms

Dirk Bausch, Mari Mino-Kenudson, Carlos Fernández-del Castillo, Andrew L. Warshaw, Kimberly A. Kelly, Sarah P. Thayer

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Introduction Pancreatic intraductal papillary mucinous neoplasms (IPMN) are now identified with increasing frequency. The detection of carcinoma in IPMN is difficult and suffers from high false-positive and false-negative rates, often resulting in inappropriate treatment decisions. Improved detection of malignancy using novel biomarkers may therefore improve diagnostic accuracy. One such promising novel biomarker is Plectin-1 (Plec-1). Methods Using immunohistochemistry, Plec-1 expression was assayed in benign (low and moderate dysplasia, n=6) as well as malignant IPMN (high-grade dysplasia and invasive carcinoma, n=31) and lymph node metastases from carcinoma arising in IPMN (n=12). Furthermore, cyst fluids from benign (n=3) and malignant IPMN (n=4) were evaluated for Plec-1 expression. Results and discussion Twenty-six of 31 malignant IPMN and all 12 lymph node metastases were Plec-1 positive. In contrast, only one of six benign IPMN expressed Plec-1. The specificity of Plec-1 in distinguishing malignant IPMN from benign IPMN was 83% and its sensitivity 84%. Furthermore, all (four out of four) cyst fluids from malignant IPMN, but one of the three benign IPMN, were Plec-1 positive. These data support Plec-1 as an excellent biomarker for the early etection of carcinoma arising in IPMN.

Original languageEnglish (US)
Pages (from-to)1948-1954
Number of pages7
JournalJournal of Gastrointestinal Surgery
Volume13
Issue number11
DOIs
StatePublished - Sep 18 2009

Fingerprint

Plectin
Biomarkers
Neoplasms
Cyst Fluid
Carcinoma
Lymph Nodes
Neoplasm Metastasis
Carcinoma, Intraductal, Noninfiltrating

Keywords

  • Biomarker
  • Malignant IPMN
  • Plectin-1

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Cite this

Plectin-1 is a biomarker of malignant pancreatic intraductal papillary mucinous neoplasms. / Bausch, Dirk; Mino-Kenudson, Mari; Fernández-del Castillo, Carlos; Warshaw, Andrew L.; Kelly, Kimberly A.; Thayer, Sarah P.

In: Journal of Gastrointestinal Surgery, Vol. 13, No. 11, 18.09.2009, p. 1948-1954.

Research output: Contribution to journalArticle

Bausch, D, Mino-Kenudson, M, Fernández-del Castillo, C, Warshaw, AL, Kelly, KA & Thayer, SP 2009, 'Plectin-1 is a biomarker of malignant pancreatic intraductal papillary mucinous neoplasms', Journal of Gastrointestinal Surgery, vol. 13, no. 11, pp. 1948-1954. https://doi.org/10.1007/s11605-009-1001-9
Bausch, Dirk ; Mino-Kenudson, Mari ; Fernández-del Castillo, Carlos ; Warshaw, Andrew L. ; Kelly, Kimberly A. ; Thayer, Sarah P. / Plectin-1 is a biomarker of malignant pancreatic intraductal papillary mucinous neoplasms. In: Journal of Gastrointestinal Surgery. 2009 ; Vol. 13, No. 11. pp. 1948-1954.
@article{e2ee2d96fd9d4422966b1ff6cb253ff0,
title = "Plectin-1 is a biomarker of malignant pancreatic intraductal papillary mucinous neoplasms",
abstract = "Introduction Pancreatic intraductal papillary mucinous neoplasms (IPMN) are now identified with increasing frequency. The detection of carcinoma in IPMN is difficult and suffers from high false-positive and false-negative rates, often resulting in inappropriate treatment decisions. Improved detection of malignancy using novel biomarkers may therefore improve diagnostic accuracy. One such promising novel biomarker is Plectin-1 (Plec-1). Methods Using immunohistochemistry, Plec-1 expression was assayed in benign (low and moderate dysplasia, n=6) as well as malignant IPMN (high-grade dysplasia and invasive carcinoma, n=31) and lymph node metastases from carcinoma arising in IPMN (n=12). Furthermore, cyst fluids from benign (n=3) and malignant IPMN (n=4) were evaluated for Plec-1 expression. Results and discussion Twenty-six of 31 malignant IPMN and all 12 lymph node metastases were Plec-1 positive. In contrast, only one of six benign IPMN expressed Plec-1. The specificity of Plec-1 in distinguishing malignant IPMN from benign IPMN was 83{\%} and its sensitivity 84{\%}. Furthermore, all (four out of four) cyst fluids from malignant IPMN, but one of the three benign IPMN, were Plec-1 positive. These data support Plec-1 as an excellent biomarker for the early etection of carcinoma arising in IPMN.",
keywords = "Biomarker, Malignant IPMN, Plectin-1",
author = "Dirk Bausch and Mari Mino-Kenudson and {Fern{\'a}ndez-del Castillo}, Carlos and Warshaw, {Andrew L.} and Kelly, {Kimberly A.} and Thayer, {Sarah P.}",
year = "2009",
month = "9",
day = "18",
doi = "10.1007/s11605-009-1001-9",
language = "English (US)",
volume = "13",
pages = "1948--1954",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "11",

}

TY - JOUR

T1 - Plectin-1 is a biomarker of malignant pancreatic intraductal papillary mucinous neoplasms

AU - Bausch, Dirk

AU - Mino-Kenudson, Mari

AU - Fernández-del Castillo, Carlos

AU - Warshaw, Andrew L.

AU - Kelly, Kimberly A.

AU - Thayer, Sarah P.

PY - 2009/9/18

Y1 - 2009/9/18

N2 - Introduction Pancreatic intraductal papillary mucinous neoplasms (IPMN) are now identified with increasing frequency. The detection of carcinoma in IPMN is difficult and suffers from high false-positive and false-negative rates, often resulting in inappropriate treatment decisions. Improved detection of malignancy using novel biomarkers may therefore improve diagnostic accuracy. One such promising novel biomarker is Plectin-1 (Plec-1). Methods Using immunohistochemistry, Plec-1 expression was assayed in benign (low and moderate dysplasia, n=6) as well as malignant IPMN (high-grade dysplasia and invasive carcinoma, n=31) and lymph node metastases from carcinoma arising in IPMN (n=12). Furthermore, cyst fluids from benign (n=3) and malignant IPMN (n=4) were evaluated for Plec-1 expression. Results and discussion Twenty-six of 31 malignant IPMN and all 12 lymph node metastases were Plec-1 positive. In contrast, only one of six benign IPMN expressed Plec-1. The specificity of Plec-1 in distinguishing malignant IPMN from benign IPMN was 83% and its sensitivity 84%. Furthermore, all (four out of four) cyst fluids from malignant IPMN, but one of the three benign IPMN, were Plec-1 positive. These data support Plec-1 as an excellent biomarker for the early etection of carcinoma arising in IPMN.

AB - Introduction Pancreatic intraductal papillary mucinous neoplasms (IPMN) are now identified with increasing frequency. The detection of carcinoma in IPMN is difficult and suffers from high false-positive and false-negative rates, often resulting in inappropriate treatment decisions. Improved detection of malignancy using novel biomarkers may therefore improve diagnostic accuracy. One such promising novel biomarker is Plectin-1 (Plec-1). Methods Using immunohistochemistry, Plec-1 expression was assayed in benign (low and moderate dysplasia, n=6) as well as malignant IPMN (high-grade dysplasia and invasive carcinoma, n=31) and lymph node metastases from carcinoma arising in IPMN (n=12). Furthermore, cyst fluids from benign (n=3) and malignant IPMN (n=4) were evaluated for Plec-1 expression. Results and discussion Twenty-six of 31 malignant IPMN and all 12 lymph node metastases were Plec-1 positive. In contrast, only one of six benign IPMN expressed Plec-1. The specificity of Plec-1 in distinguishing malignant IPMN from benign IPMN was 83% and its sensitivity 84%. Furthermore, all (four out of four) cyst fluids from malignant IPMN, but one of the three benign IPMN, were Plec-1 positive. These data support Plec-1 as an excellent biomarker for the early etection of carcinoma arising in IPMN.

KW - Biomarker

KW - Malignant IPMN

KW - Plectin-1

UR - http://www.scopus.com/inward/record.url?scp=77952993051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952993051&partnerID=8YFLogxK

U2 - 10.1007/s11605-009-1001-9

DO - 10.1007/s11605-009-1001-9

M3 - Article

C2 - 19760374

AN - SCOPUS:77952993051

VL - 13

SP - 1948

EP - 1954

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 11

ER -